Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07496450 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
A Phase 3 study, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,000
- Enrollment target
NCT07496450 is a Phase 3 study that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 4,000 participants.
The verdict
NCT07496450, a Phase 3 study, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,000 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1018-H5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2027-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07496450
The ClinicalTrials.gov registry entry for NCT07496450 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07496450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07496450 about?
NCT07496450 is a clinical study titled "A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults". The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
What is the current status of trial NCT07496450?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,000 participants. The study started on 2026-03-23. Estimated completion is 2027-01-28.
What interventions are being tested in trial NCT07496450?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1018-H5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07496450?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.